{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:54:58Z","timestamp":1791975298711,"version":"4.4.0"},"reference-count":22,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Patients with breast cancer planned for neoadjuvant chemotherapy (NAC) represent a diverse population including high-risk early breast cancer (EBC) and locally advanced breast cancer (LABC). Staging investigations are routinely performed, but the clinical utility is unclear. Methods: Using a provincial cancer registry, we identified breast cancer patients referred for NAC between 2020 and 2022. Patients with staging investigations were stratified into EBC (anatomic clinical stage I\u2013II) and LABC (stage III). Rates of metastatic (M1) disease and associated factors were assessed. Results: Among 529 EBC patients, 515 (97.4%) underwent staging. The M1 disease rate was 5.4%. The M1 rate for cT1-2N0 was 1.1%, and for cT1-2N1 it was 7.9%. In multivariable analysis, cT1N1 (OR 5.31; 95% CI 1.05\u201327.0; p = 0.044) and cT2N1 (OR 4.59; 95% CI 1.02\u201320.67; p = 0.047) were associated with M1 disease in EBC. All 320 LABC patients underwent staging. The M1 disease rate was 22.8%, significantly higher than in EBC (p &lt; 0.001). A higher cT\/N stage correlated with M1 disease in LABC, although most subgroups demonstrated rates of \u226510%. Conclusions: These findings support a risk-adapted approach to pre-treatment staging in patients planned for NAC, omitting staging in asymptomatic cT1\u20132N0 disease, considering it for node-positive EBC, and performing it routinely in LABC.<\/jats:p>","DOI":"10.3390\/curroncol33040203","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:09:21Z","timestamp":1775038161000},"page":"203","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Yield of Staging Investigations in Patients with Breast Cancer Planned for Neoadjuvant Chemotherapy"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2855-5919","authenticated-orcid":false,"given":"Kadhim","family":"Taqi","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Division of Surgical Oncology, Department of Surgery, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia","family":"Ursu","sequence":"additional","affiliation":[{"name":"Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Isherwood","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Raheel","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Downey","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Q.","family":"Cao","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Arthur J.E. Child Comprehensive Cancer Centre, Calgary, AB T2N 1N4, Canada"},{"name":"Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9545-0802","authenticated-orcid":false,"given":"Sasha","family":"Lupichuk","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-5360","authenticated-orcid":false,"given":"Omar","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Nixon","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Lynn","family":"Quan","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Department of Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Laws","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"ref_1","unstructured":"Gradishar, W., Moran, M., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K., Anderson, B., Bailey, J., and Burstein, H. (2025). National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"ref_2","unstructured":"American Society of Clinical Oncology, and American Board of Internal Medicine (2025, October 20). Choosing Wisely: Cancer Tests and Treatments. Published 2012. Available online: http:\/\/www.choosingwisely.org\/patient-resources\/cancer-tests-and-treatments."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.3747\/co.27.6147","article-title":"Baseline staging imaging for distant metastasis in women with stage I, II, and III breast cancer","volume":"27","author":"Arnaout","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_5","unstructured":"American Society of Clinical Oncology (2025, November 02). Choosing Wisely. ASCO. Available online: https:\/\/www.asco.org\/news-initiatives\/current-initiatives\/cancer-care-initiatives\/value-cancer-care\/choosing-wisely."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Expert Panel on Breast Imaging, McDonald, E.S., Scheel, J.R., Lewin, A.A., Weinstein, S., Dodelzon, K., Dogan, B., Fitzpatrick, A., Kuzmiak, C., and Newell, M. (2024). ACR Appropriateness Criteria\u00ae Imaging of Invasive Breast Cancer. J. Am. Coll. Radiol., 21, S168\u2013S202.","DOI":"10.1016\/j.jacr.2024.02.021"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1245\/s10434-019-07543-0","article-title":"Overuse of preoperative staging of patients undergoing neoadjuvant chemotherapy for breast cancer","volume":"26","author":"Srour","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"zraa006","DOI":"10.1093\/bjsopen\/zraa006","article-title":"Expanded criteria for pretreatment staging CT in breast cancer","volume":"5","author":"Roszkowski","year":"2021","journal-title":"BJS Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1111\/tbj.13931","article-title":"Outcome of CT staging prior to neoadjuvant chemotherapy in patients with early breast cancer","volume":"26","author":"Broadbent","year":"2020","journal-title":"Breast J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/tbj.14172","article-title":"Incidental radiologic findings in breast cancer patients who undergo staging prior to neoadjuvant chemotherapy","volume":"27","author":"Srour","year":"2021","journal-title":"Breast J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.3390\/curroncol28030203","article-title":"Staging investigations in asymptomatic early breast cancer patients at the Cancer Centre of Southeastern Ontario","volume":"28","author":"Kamel","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1200\/JCO.2005.01.6089","article-title":"Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer","volume":"24","author":"Lohrisch","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1634\/theoncologist.2016-0157","article-title":"Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer","volume":"21","author":"Bychkovsky","year":"2016","journal-title":"Oncologist"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/sj.bjc.6605323","article-title":"Radiological staging in breast cancer: Which asymptomatic patients to image and how","volume":"101","author":"Barrett","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4274\/ejbh.galenos.2024.2024-1-6","article-title":"Need for staging investigations in newly diagnosed breast cancer: Establishing local guidelines for radiological staging in Bahrain","volume":"20","author":"Alkazaz","year":"2024","journal-title":"Eur. J. Breast Health"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/GO.20.00257","article-title":"Clinicopathologic features predictive of distant metastasis in patients diagnosed with invasive breast cancer","volume":"6","author":"Ali","year":"2020","journal-title":"JCO Glob. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101854","DOI":"10.1016\/j.suronc.2022.101854","article-title":"The effect of delayed treatment in breast cancer patients: How much is too late? An experience of a single-center study effect of surgery delay in survival","volume":"44","author":"Luz","year":"2022","journal-title":"Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/jamasurg.2022.8388","article-title":"Reexamining time from breast cancer diagnosis to primary breast surgery","volume":"158","author":"Wiener","year":"2023","journal-title":"JAMA Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/jamaoncol.2015.4508","article-title":"Time to surgery and breast cancer survival in the United States","volume":"2","author":"Bleicher","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2012.41.7972","article-title":"Preoperative delays in the US Medicare population with breast cancer","volume":"30","author":"Bleicher","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","article-title":"Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer (endorsed by the ACR, ESSO, ESTRO, EUSOBI\/ESR, and EUSOMA)","volume":"51","author":"Vaz","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/203\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:46:06Z","timestamp":1775040366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["curroncol33040203"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33040203","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}